<!doctype html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Cardiomyopathies - Clinical Study Note</title>
    <style>
      :root {
        --bg: #f8fbff;
        --surface: #ffffff;
        --ink: #132741;
        --muted: #566c84;
        --line: #d7e3f0;
        --brand: #6b2f8a;
        --brand-soft: #f8f0ff;
        --teal-soft: #eef9f7;
        --warn-soft: #fff7e8;
        --danger-soft: #fff0f0;
      }

      * {
        box-sizing: border-box;
      }

      body {
        margin: 0;
        font-family: "Segoe UI", Tahoma, Arial, sans-serif;
        color: var(--ink);
        background:
          radial-gradient(circle at 84% 8%, #ead8ff 0%, transparent 31%),
          radial-gradient(circle at 9% 22%, #e1f4ff 0%, transparent 24%),
          var(--bg);
      }

      .wrap {
        width: min(1240px, 94vw);
        margin: 22px auto 34px;
        display: grid;
        grid-template-columns: 290px 1fr;
        gap: 16px;
      }

      .panel {
        background: var(--surface);
        border: 1px solid var(--line);
        border-radius: 16px;
        box-shadow: 0 10px 24px rgba(13, 34, 62, 0.06);
      }

      .toc {
        position: sticky;
        top: 16px;
        max-height: calc(100dvh - 32px);
        overflow: auto;
        padding: 14px;
      }

      .toc h2 {
        margin: 0 0 10px;
        color: var(--brand);
        font-size: 1rem;
      }

      .toc a {
        display: block;
        text-decoration: none;
        color: #374d68;
        border-radius: 8px;
        padding: 7px 9px;
        font-size: 13px;
      }

      .toc a:hover {
        background: #f8f2ff;
        color: #5b2975;
      }

      .content {
        padding: 0 0 18px;
      }

      .hero {
        padding: 20px;
        border-bottom: 1px solid var(--line);
        background: linear-gradient(160deg, #fffefe 0%, #f8f1ff 56%, #eef9f7 100%);
      }

      .eyebrow {
        display: inline-flex;
        align-items: center;
        min-height: 28px;
        padding: 5px 12px;
        border-radius: 999px;
        background: var(--brand-soft);
        color: #6b2f8a;
        font-size: 12px;
        font-weight: 700;
        margin-bottom: 10px;
      }

      h1 {
        margin: 0;
        color: #54256d;
        font-size: clamp(1.42rem, 2.4vw, 2.04rem);
      }

      .subtitle {
        margin: 8px 0 0;
        color: var(--muted);
        line-height: 1.55;
      }

      .hero-layout {
        margin-top: 14px;
        display: grid;
        grid-template-columns: 1.35fr 0.95fr;
        gap: 12px;
      }

      .hero-grid {
        display: grid;
        grid-template-columns: repeat(4, minmax(0, 1fr));
        gap: 10px;
      }

      .metric {
        border: 1px solid #e6d4f2;
        border-radius: 12px;
        background: #fff;
        padding: 10px;
      }

      .metric .k {
        font-size: 11px;
        color: #786487;
        margin-bottom: 6px;
        text-transform: uppercase;
        letter-spacing: 0.3px;
      }

      .metric .v {
        font-size: 14px;
        color: #54256d;
        font-weight: 700;
      }

      .hero-visual {
        border: 1px solid #e8d8f2;
        border-radius: 14px;
        background: #fff;
        padding: 10px;
        display: grid;
        gap: 8px;
      }

      .hero-visual h3 {
        margin: 0;
        font-size: 0.95rem;
        color: #5e2a7a;
      }

      .hero-visual p {
        margin: 0;
        font-size: 0.84rem;
        color: #5d758c;
      }

      .hero-visual svg {
        width: 100%;
        height: auto;
        display: block;
      }

      .section {
        padding: 16px 20px;
        border-bottom: 1px solid #edf3fb;
      }

      .section:last-child {
        border-bottom: none;
      }

      .section h2 {
        margin: 0 0 10px;
        color: #5d2a79;
        font-size: 1.16rem;
      }

      .section p {
        margin: 0;
        color: #314860;
        line-height: 1.56;
      }

      .stack {
        margin-top: 10px;
        display: grid;
        gap: 10px;
      }

      .grid-2 {
        display: grid;
        grid-template-columns: repeat(2, minmax(0, 1fr));
        gap: 10px;
      }

      .grid-3 {
        display: grid;
        grid-template-columns: repeat(3, minmax(0, 1fr));
        gap: 10px;
      }

      .box {
        border: 1px solid var(--line);
        border-radius: 12px;
        padding: 11px 12px;
        background: #fff;
      }

      .box h3 {
        margin: 0 0 7px;
        font-size: 0.97rem;
        color: #1f4061;
      }

      .box p {
        margin: 0;
      }

      .box ul {
        margin: 0 0 0 17px;
        padding: 0;
      }

      .box li {
        margin: 4px 0;
        color: #304860;
      }

      .table {
        margin-top: 8px;
        width: 100%;
        border-collapse: collapse;
        border-radius: 12px;
        border: 1px solid var(--line);
        overflow: hidden;
      }

      .table th,
      .table td {
        padding: 10px;
        text-align: left;
        font-size: 14px;
        border-bottom: 1px solid #e8eff8;
        vertical-align: top;
      }

      .table th {
        background: #f8f2ff;
        color: #5e2a79;
      }

      .table tr:last-child td {
        border-bottom: none;
      }

      .chips {
        margin-top: 8px;
        display: flex;
        gap: 8px;
        flex-wrap: wrap;
      }

      .chip {
        display: inline-flex;
        align-items: center;
        min-height: 30px;
        padding: 4px 10px;
        border-radius: 999px;
        border: 1px solid #d8e4f2;
        background: #f8fbff;
        color: #254764;
        font-size: 13px;
        font-weight: 600;
      }

      .callout {
        margin-top: 10px;
        border-left: 4px solid #0f766e;
        border-radius: 10px;
        background: var(--teal-soft);
        color: #175358;
        padding: 10px 12px;
      }

      .callout.warn {
        border-left-color: #b66a00;
        background: var(--warn-soft);
        color: #7c5b1d;
      }

      .callout.alert {
        border-left-color: #b91c1c;
        background: var(--danger-soft);
        color: #6d2222;
      }

      .flow {
        margin-top: 10px;
        display: grid;
        gap: 9px;
      }

      .step {
        border: 1px solid #d5e3f4;
        border-radius: 12px;
        padding: 10px 11px;
        background: #f9fcff;
      }

      .step strong {
        color: #5e2a79;
      }

      .arrow {
        width: 30px;
        height: 30px;
        margin: 0 auto;
        border-radius: 999px;
        border: 1px solid #c9d8ec;
        background: #f6fbff;
        color: #456887;
        font-weight: 900;
        display: grid;
        place-items: center;
        line-height: 1;
      }

      .diagram-card {
        margin-top: 10px;
        border: 1px solid #d8e4f2;
        border-radius: 12px;
        background: #fbfdff;
        padding: 11px;
      }

      .diagram-title {
        margin: 0 0 8px;
        font-size: 0.9rem;
        color: #1d3f62;
        font-weight: 700;
      }

      .refs a {
        color: #145aa9;
        text-decoration: none;
        word-break: break-word;
      }

      .refs a:hover {
        text-decoration: underline;
      }

      @media (max-width: 1040px) {
        .wrap {
          grid-template-columns: 1fr;
        }

        .toc {
          position: static;
          max-height: none;
        }

        .hero-layout {
          grid-template-columns: 1fr;
        }

        .hero-grid {
          grid-template-columns: repeat(2, minmax(0, 1fr));
        }
      }

      @media (max-width: 760px) {
        .grid-2,
        .grid-3,
        .hero-grid {
          grid-template-columns: 1fr;
        }
      }
    </style>
  </head>
  <body>
    <div class="wrap">
      <aside class="panel toc">
        <h2>On This Page</h2>
        <a href="#what-are-cardiomyopathies">1. What Are Cardiomyopathies?</a>
        <a href="#dilated-cardiomyopathy">2. Dilated Cardiomyopathy</a>
        <a href="#hypertrophic-cardiomyopathy">3. Hypertrophic Cardiomyopathy</a>
        <a href="#restrictive-cardiomyopathy">4. Restrictive Cardiomyopathy</a>
        <a href="#sudden-cardiac-death-risk">5. Sudden Cardiac Death Risk</a>
        <a href="#management-recap-drill">Recap Drill</a>
        <a href="#exam-traps">6. Common Exam Traps</a>
        <a href="#quick-revision">7. Quick Revision Summary</a>
      </aside>

      <article class="panel content">
        <header class="hero">
          <span class="eyebrow">Cardiovascular Disorders</span>
          <h1>Cardiomyopathies</h1>
          <p class="subtitle">
            Clinical overview and exam mastery guide for dilated, hypertrophic,
            and restrictive cardiomyopathy with high-yield pharmacology and ICD risk strategy.
          </p>

          <div class="hero-layout">
            <div class="hero-grid">
              <div class="metric">
                <div class="k">DCM</div>
                <div class="v">Dilation and reduced EF</div>
              </div>
              <div class="metric">
                <div class="k">HCM</div>
                <div class="v">Hypertrophy and LVOT risk</div>
              </div>
              <div class="metric">
                <div class="k">RCM</div>
                <div class="v">Stiff ventricle, preserved EF</div>
              </div>
              <div class="metric">
                <div class="k">Sudden Death Prevention</div>
                <div class="v">ICD in high-risk patients</div>
              </div>
            </div>

            <div class="hero-visual">
              <h3>Classification Snapshot</h3>
              <svg viewBox="0 0 500 220" role="img" aria-label="Cardiomyopathy classification diagram">
                <rect x="0" y="0" width="500" height="220" rx="14" fill="#fbfdff" />
                <rect x="20" y="28" width="146" height="72" rx="10" fill="#f8f2ff" stroke="#e7d8f2" />
                <text x="93" y="53" text-anchor="middle" font-size="13" fill="#5d2a79" font-weight="700">DCM</text>
                <text x="93" y="71" text-anchor="middle" font-size="12" fill="#6f6280">Dilated</text>
                <text x="93" y="87" text-anchor="middle" font-size="12" fill="#6f6280">Low EF</text>

                <rect x="176" y="28" width="146" height="72" rx="10" fill="#eef7ff" stroke="#d8e6f6" />
                <text x="249" y="53" text-anchor="middle" font-size="13" fill="#1f4467" font-weight="700">HCM</text>
                <text x="249" y="71" text-anchor="middle" font-size="12" fill="#5f7488">Hypertrophy</text>
                <text x="249" y="87" text-anchor="middle" font-size="12" fill="#5f7488">LVOT obstruction</text>

                <rect x="332" y="28" width="146" height="72" rx="10" fill="#eefaf7" stroke="#d4ece4" />
                <text x="405" y="53" text-anchor="middle" font-size="13" fill="#1c564f" font-weight="700">RCM</text>
                <text x="405" y="71" text-anchor="middle" font-size="12" fill="#5b7a74">Stiff ventricle</text>
                <text x="405" y="87" text-anchor="middle" font-size="12" fill="#5b7a74">Preserved EF</text>

                <rect x="20" y="128" width="458" height="68" rx="10" fill="#ffffff" stroke="#d8e4f2" />
                <text x="249" y="154" text-anchor="middle" font-size="13" fill="#2a4963" font-weight="700">
                  Key Exam Axis: hemodynamics + sudden death risk
                </text>
                <text x="249" y="172" text-anchor="middle" font-size="12" fill="#42607b">
                  DCM -> HF therapy | HCM -> rate/contractility control | RCM -> underlying cause focus
                </text>
              </svg>
              <p>Different morphology patterns drive different treatment priorities.</p>
            </div>
          </div>
        </header>

        <section class="section" id="what-are-cardiomyopathies">
          <h2>1. What Are Cardiomyopathies?</h2>
          <p>
            Cardiomyopathies are diseases of cardiac muscle that impair pump
            function and/or ventricular filling. Core categories include
            dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM),
            and restrictive cardiomyopathy (RCM).
          </p>
          <div class="chips">
            <span class="chip">Dilated cardiomyopathy</span>
            <span class="chip">Hypertrophic cardiomyopathy</span>
            <span class="chip">Restrictive cardiomyopathy</span>
          </div>
        </section>

        <section class="section" id="dilated-cardiomyopathy">
          <h2>2. Dilated Cardiomyopathy (DCM)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Pathophysiology and Causes</h3>
              <ul>
                <li>Ventricular dilation with reduced systolic function</li>
                <li>Decreased ejection fraction and HFrEF progression</li>
                <li>Common causes: idiopathic, viral myocarditis, alcohol, anthracyclines, genetics</li>
              </ul>
            </div>
            <div class="box">
              <h3>Clinical Features</h3>
              <ul>
                <li>Dyspnea</li>
                <li>Fatigue</li>
                <li>Peripheral edema</li>
                <li>Signs of heart failure</li>
              </ul>
            </div>
          </div>

          <table class="table">
            <thead>
              <tr>
                <th>Core DCM Therapy</th>
                <th>MOA</th>
                <th>Major Side Effects</th>
                <th>Contraindications / Cautions</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>ARNI / ACE inhibitor / ARB</td>
                <td>RAAS pathway suppression and/or neprilysin modulation to reduce afterload/remodeling</td>
                <td>Hypotension, hyperkalemia, renal dysfunction, cough (ACE inhibitor)</td>
                <td>Pregnancy; angioedema history for ARNI/ACE inhibitor contexts</td>
              </tr>
              <tr>
                <td>Evidence-based beta blockers</td>
                <td>Reduce adrenergic drive, lower HR, improve remodeling over time</td>
                <td>Bradycardia, fatigue, hypotension</td>
                <td>Cardiogenic shock, severe bradycardia, unstable decompensation at initiation</td>
              </tr>
              <tr>
                <td>MRA (spironolactone/eplerenone)</td>
                <td>Aldosterone receptor blockade, reduced fibrosis/remodeling</td>
                <td>Hyperkalemia, renal dysfunction, gynecomastia (spironolactone)</td>
                <td>Severe renal impairment, significant hyperkalemia</td>
              </tr>
              <tr>
                <td>SGLT2 inhibitors</td>
                <td>Renal sodium-glucose transport inhibition with cardiorenal benefit</td>
                <td>Volume depletion, genital infections, rare euglycemic DKA</td>
                <td>Severe renal dysfunction (agent specific), type 1 diabetes</td>
              </tr>
              <tr>
                <td>Loop diuretics (symptom control)</td>
                <td>Na-K-2Cl inhibition in loop of Henle to reduce congestion</td>
                <td>Hypokalemia, hypotension, dehydration</td>
                <td>Use with electrolyte and renal monitoring</td>
              </tr>
            </tbody>
          </table>

          <div class="callout">
            Treat DCM as HFrEF. In severely reduced EF with high arrhythmic risk, evaluate for ICD.
          </div>
        </section>

        <section class="section" id="hypertrophic-cardiomyopathy">
          <h2>3. Hypertrophic Cardiomyopathy (HCM)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Pathophysiology and Risk</h3>
              <ul>
                <li>Asymmetric septal hypertrophy</li>
                <li>Dynamic LV outflow tract obstruction (obstructive subtype)</li>
                <li>Diastolic dysfunction</li>
                <li>Sudden cardiac death risk, especially in young athletes</li>
              </ul>
            </div>
            <div class="box">
              <h3>Symptoms</h3>
              <ul>
                <li>Syncope</li>
                <li>Dyspnea</li>
                <li>Chest pain</li>
              </ul>
            </div>
          </div>

          <table class="table">
            <thead>
              <tr>
                <th>HCM Therapy</th>
                <th>MOA</th>
                <th>Major Side Effects</th>
                <th>Contraindications / Cautions</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td>Beta blockers (first-line)</td>
                <td>Lower HR and contractility, improve diastolic filling, reduce LVOT obstruction</td>
                <td>Bradycardia, fatigue</td>
                <td>Severe bradycardia, cardiogenic shock</td>
              </tr>
              <tr>
                <td>Non-DHP CCB (verapamil)</td>
                <td>Lower contractility and improve diastolic relaxation</td>
                <td>Bradycardia, hypotension, constipation</td>
                <td>Avoid in severe obstruction with hypotension</td>
              </tr>
              <tr>
                <td>Disopyramide (obstructive HCM add-on)</td>
                <td>Class IA sodium channel blockade with negative inotropic effect</td>
                <td>Anticholinergic effects, QT prolongation</td>
                <td>Baseline prolonged QT or major proarrhythmic risk</td>
              </tr>
            </tbody>
          </table>

          <div class="callout alert">
            High-yield trap: avoid preload-reducing drugs in severe obstructive HCM
            (nitrates, aggressive diuresis, and vasodilators such as ACE inhibitors in severe obstruction)
            because obstruction can worsen.
          </div>
        </section>

        <section class="section" id="restrictive-cardiomyopathy">
          <h2>4. Restrictive Cardiomyopathy (RCM)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Pathophysiology and Causes</h3>
              <ul>
                <li>Stiff ventricles with impaired diastolic filling</li>
                <li>Ejection fraction often preserved</li>
                <li>Common causes: amyloidosis, hemochromatosis, sarcoidosis</li>
              </ul>
            </div>
            <div class="box">
              <h3>Clinical Pattern and Strategy</h3>
              <ul>
                <li>Right-sided heart failure features, fatigue, edema</li>
                <li>Treat underlying disease</li>
                <li>Use diuretics cautiously for symptoms</li>
                <li>Manage arrhythmias as needed</li>
              </ul>
            </div>
          </div>
          <div class="callout warn">
            There is no universal curative pharmacotherapy for RCM; treatment is cause-specific plus symptom control.
          </div>
        </section>

        <section class="section" id="sudden-cardiac-death-risk">
          <h2>5. Sudden Cardiac Death Risk</h2>
          <p>
            In HCM and severe DCM, evaluate for high-risk markers and ICD candidacy.
          </p>
          <div class="chips">
            <span class="chip">Family history of sudden death</span>
            <span class="chip">Severe LV hypertrophy</span>
            <span class="chip">Syncope</span>
            <span class="chip">Ventricular arrhythmias</span>
          </div>
          <div class="callout">
            ICD therapy is a key prevention strategy in high-risk cardiomyopathy patients.
          </div>
        </section>

        <section class="section" id="management-recap-drill">
          <h2>Management Recap Drill</h2>
          <div class="flow">
            <div class="step"><strong>DCM:</strong> treat as HFrEF with full guideline-directed therapy.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>DCM severe EF reduction:</strong> assess ICD indications.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>HCM:</strong> beta blocker first-line, then verapamil/disopyramide when indicated.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>HCM:</strong> avoid strong preload reduction in severe obstructive disease.</div>
            <div class="arrow" aria-hidden="true">&#8595;</div>
            <div class="step"><strong>RCM:</strong> treat underlying cause and control symptoms cautiously.</div>
          </div>

          <div class="diagram-card">
            <p class="diagram-title">Visual Algorithm Placeholder</p>
            <p>
              [Insert Cardiomyopathy Classification and Management Flowchart Here During UI Integration]
            </p>
          </div>
        </section>

        <section class="section refs">
          <h2>Guideline References (Management)</h2>
          <div class="grid-2">
            <div class="box">
              <h3>ACC/AHA Guideline for Hypertrophic Cardiomyopathy</h3>
              <a href="https://www.acc.org/guidelines" target="_blank" rel="noopener">
                https://www.acc.org/guidelines
              </a>
            </div>
            <div class="box">
              <h3>ACC/AHA Heart Failure Guidelines (DCM Framework)</h3>
              <a href="https://www.acc.org/guidelines" target="_blank" rel="noopener">
                https://www.acc.org/guidelines
              </a>
            </div>
          </div>
        </section>

        <section class="section" id="exam-traps">
          <h2>6. Common Exam Traps</h2>
          <div class="stack">
            <div class="callout alert">HCM with severe obstruction: avoid aggressive preload reduction.</div>
            <div class="callout alert">DCM management follows HFrEF treatment principles.</div>
            <div class="callout alert">RCM often presents with preserved EF despite severe filling abnormality.</div>
            <div class="callout alert">Young athlete sudden death pattern should raise concern for HCM.</div>
            <div class="callout alert">ICD decisions are central in high-risk cardiomyopathy.</div>
          </div>
        </section>

        <section class="section" id="quick-revision">
          <h2>7. Quick Revision Summary</h2>
          <div class="grid-2">
            <div class="box">
              <h3>Must Remember</h3>
              <ul>
                <li>DCM = dilation with reduced EF</li>
                <li>HCM = hypertrophy with possible dynamic LVOT obstruction</li>
                <li>RCM = stiff ventricle with impaired filling</li>
                <li>HCM core drug: beta blocker</li>
                <li>DCM requires comprehensive HF therapy</li>
              </ul>
            </div>
            <div class="box">
              <h3>Practice Questions Placeholder</h3>
              <ul>
                <li>Topic: Cardiomyopathies</li>
                <li>
                  Subtopics: dilated cardiomyopathy, hypertrophic cardiomyopathy,
                  restrictive cardiomyopathy, ICD indications, sudden death risk
                </li>
              </ul>
            </div>
          </div>
        </section>
      </article>
    </div>
  </body>
</html>
